ADEFOVIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H12N5O4P
Molecular Weight	273.1857
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O

InChI

InChIKey=SUPKOOSCJHTBAH-UHFFFAOYSA-N

InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C8H12N5O4P
Molecular Weight	273.1857
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/14498759 http://link.springer.com/chapter/10.1007%2F978-0-387-49785-3_33

The potential antiviral effect of adefovir, an acyclic nucleoside phosphonate analog of 2′-deoxyadenosine monophosphate, was first studied by Holý and De Clercq in 1980s. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. Oral adefovir dipivoxil is effective and generally well tolerated in HBeAg-positive and -negative patients chronically infected with wild-type or lamivudine-resistant HBV.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Multidrug resistance-associated protein 4 14 Target ID: CHEMBL1743128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23956101	Inhibitor 8228	133.0 µM [IC50]
Bile salt export pump 15 Target ID: CHEMBL6020 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23956101	Inhibitor 8228	46.0 µM [IC50]
Canalicular multispecific organic anion transporter 1 21 Target ID: CHEMBL5748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23956101	Inhibitor 8228	133.0 µM [IC50]
Canalicular multispecific organic anion transporter 2 8 Target ID: CHEMBL5918 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23956101	Inhibitor 8228	133.0 µM [IC50]
DNA polymerase/reverse transcriptase 10 Target ID: CHEMBL2362994 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf	Inhibitor 8228	0.1 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic hepatitis B 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf	Primary		Approved 8360	HEPSERA Approved Use HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. For patients 12 to <18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function. HEPSERA is a nucleotide analogue indicated for the treatment of chronic hepatitis B in patients ≥12 years of age. (1) Launch Date 1.03248003E12

C_max

Value	Dose	Co-administered	Analyte	Population
18.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021449s009lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		ADEFOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
220 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021449s009lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		ADEFOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.48 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021449s009lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		ADEFOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
96% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021449s009lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		ADEFOVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 12 - 17 years n = 15 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 12 - 17 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	Other AEs: Rhinorrhea, Sneezing... Other AEs: Rhinorrhea (1 patient) Sneezing (1 patient) Blister (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
0.3 mg/kg 1 times / day multiple, oral Recommended Dose: 0.3 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 2 - 6 years n = 13 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 2 - 6 years Sex: M+F Population Size: 13 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
0.3 mg/kg 1 times / day multiple, oral Recommended Dose: 0.3 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 7 - 11 years n = 19 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 7 - 11 years Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	Other AEs: Headache, Vertigo... Other AEs: Headache (1 patient) Vertigo (1 patient) Disturbance in attention (1 patient) Disorder eye (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/

AEs

AE	Significance	Dose	Population
Blister	1 patient	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 12 - 17 years n = 15 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 12 - 17 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
Rhinorrhea	1 patient	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 12 - 17 years n = 15 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 12 - 17 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
Sneezing	1 patient	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 12 - 17 years n = 15 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 12 - 17 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
Disorder eye	1 patient	0.3 mg/kg 1 times / day multiple, oral Recommended Dose: 0.3 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 7 - 11 years n = 19 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 7 - 11 years Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
Disturbance in attention	1 patient	0.3 mg/kg 1 times / day multiple, oral Recommended Dose: 0.3 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 7 - 11 years n = 19 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 7 - 11 years Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
Headache	1 patient	0.3 mg/kg 1 times / day multiple, oral Recommended Dose: 0.3 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 7 - 11 years n = 19 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 7 - 11 years Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/
Vertigo	1 patient	0.3 mg/kg 1 times / day multiple, oral Recommended Dose: 0.3 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.3 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/	unhealthy, 7 - 11 years n = 19 Health Status: unhealthy Condition: chronic hepatitis B Age Group: 7 - 11 years Sex: M+F Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/18276803/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579 substrate 1709	inhibitor 1752 substrate 1010	inhibitor 1837 substrate 1193

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2C19 1463 P-gp 1437	OAT1 320 OCT2 348 MRP4 75 CYP1A2 1032 CYP2C19 985 P-gp 1527	CYP 76

Drug as perpetrator

Target	Modality	Activity
CYP 146	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 6, 16	inconclusive
P-gp 1626	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P2.pdf Page: 26.0	inconclusive
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no

Drug as victim

Target	Modality	Activity
P-gp 1527	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P2.pdf Page: 26.0	inconclusive
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP2C9 1010	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-449_Hepsera_biopharmr_P1.pdf Page: 15.0	no
OCT2 348	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16454695/	no
MRP4 75	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16454695/	yes
OAT1 320	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16454695/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2469	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2469
ChemicalBook	CB2698137	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2698137
ZINC	ZINC000021297308	http://zinc15.docking.org/substances/ZINC000021297308
eMolecules	901335	https://www.emolecules.com/cgi-bin/more?vid=901335

PubMed

Title	Date	PubMed
Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine.	1991 Jan 5	1845964
Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine.	1992 Sep	1332606
Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.	2000 Jan	10718947
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].	2000 Jul	10950391
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.	2001 Jun	11353615
Intramolecular stacking interactions in ternary copper(II) complexes formed with 2,2'-bipyridine or 1,10-phenanthroline and 9-(4-phosphonobutyl)adenine (dPMEA), the carba relative of the antiviral nucleotide analogue 9.	2001 Mar	11330480
Formation of ternary complexes by coordination of (diethylenetriamine)-platinum(II) to N1 or N7 of the adenine moiety of the antiviral nucleotide analogue 9.	2001 May 4	11405468
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.	2001 Oct 25	11606136
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.	2001 Sep	11502520
Fanconi syndrome and renal failure induced by tenofovir: a first case report.	2002 Dec	12460055
Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates.	2002 Jul	12069973
Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures.	2002 Nov	12384336
Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.	2002 Sep	12198665
Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus.	2002 Sep	12183240
In vitro activity of potential anti-poxvirus agents.	2003 Jan	12615301
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.	2003 Jan	12500185
Intrinsic acid-base properties of purine derivatives in aqueous solution and comparison of the acidifying effects of platinum(II) coordinated to N1 or N7: acidifying effects are reciprocal and the proton "outruns" divalent metal ions.	2003 Jan 13	12513075
Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.	2003 Jul	12821467
Nickel(II), copper(II) and zinc(II) complexes of 9-[2- (phosphonomethoxy)ethyl]-8-azaadenine (9,8aPMEA), the 8-aza derivative of the antiviral nucleotide analogue 9-[2-(phosphonomethoxy)ethyl] adenine (PMEA). Quantification of four isomeric species in aqueous solution.	2004	18365084
Quantification of isomeric equilibria formed by metal ion complexes of 8-[2-(phosphonomethoxy)ethyl]-8-azaadenine (8,8aPMEA) and 9-[2-(phosphonomethoxy)ethyl]-8-azaadenine (9,8aPMEA). Derivatives of the antiviral nucleotide analogue 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).	2004 Dec	15503234
Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.	2004 Jun	15155222
In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?	2004 Mar	15168799
Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.	2004 Oct	15388423
Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.	2005	16247948
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.	2005	16152756
cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach.	2005 Dec 15	16335932
Acid-base and metal-ion-binding properties of 9-[2-(2-phosphonoethoxy)ethyl]adenine (PEEA), a relative of the antiviral nucleotide analogue 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). An exercise on the quantification of isomeric complex equilibria in solution.	2005 Jul 11	15998039
Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities.	2005 Mar	15728921
Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.	2005 Mar	15728906
Spectrum of antiviral activity of o-(acetoxyphenyl)hept-2-ynyl sulphide (APHS).	2005 May	15848298
The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3.	2006 Dec	16857889
Cellular and virological mechanisms of HBV drug resistance.	2006 Feb	16364492
Virologic response and resistance to adefovir in patients with chronic hepatitis B.	2006 Feb	16338024
Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine.	2006 Jan 13	16371225
In vivo effects of antiviral acyclic nucleoside phosphonate 9-[2-(phosphonomethoxy)ethyl]adenine (adefovir) on cytochrome P450 system of rat liver microsomes.	2006 May	16416053
Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy.	2006 Nov	17052272
Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro.	2006 Oct	16630664
Successful treatment of an entecavir-resistant hepatitis B virus variant.	2007 Dec	17935165
Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.	2007 Jan	17124193
Design and synthesis of novel bis(L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) with improved anti-HBV activity.	2007 Jan 15	17074481
Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.	2007 Jul 15	17638908
Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.	2007 Nov	17854030
Secretion of antiretroviral chemokines by human cells cultured with acyclic nucleoside phosphonates.	2007 Nov 21	17716649
In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations.	2007 Oct	17687019
Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.	2007 Oct	17404847
Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years.	2008 Jan	17983429
[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].	2008 Mar	18367858
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B.	2008 Mar 21	18350610
Gene induction for the treatment of methylmalonic aciduria.	2009 Apr	19199343
Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.	2009 Jan	19203548

Patents

Sample Use Guides

In Vivo Use Guide

One tablet containing 10 mg adefovir dipivoxil once daily orally

Route of Administration: Oral

In Vitro Use Guide

The concentration of adefovir that inhibited 50% of viral DNA synthesis (EC50) in HBV transfected human hepatoma cell lines ranged from 0.2 to 2.5 uM.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 23:12:51 UTC 2023` Edited by `admin` on `Thu Jul 06 23:12:51 UTC 2023`
Record UNII	6GQP90I798
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ADEFOVIR

Official Name

English

adefovir [INN]

Common Name

English

ADEFOVIR [VANDF]

Common Name

English

GS 0393

Code

English

ADEFOVIR [USAN]

Common Name

English

[[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosphonic acid

Systematic Name

English

PHOSPHONIC ACID, ((2-(6-AMINO-9H-PURIN-9-YL)ETHOXY)METHYL)-

Common Name

English

Adefovir [WHO-DD]

Common Name

English

PMEA

Common Name

English

GS-0393

Code

English

9-(2-(PHOSPHONOMETHOXY)ETHYL)ADENINE

Systematic Name

English

ADEFOVIR [MI]

Common Name

English

9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE

Common Name

English

ADEFOVIR [MART.]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175459